ISOTOPE: ISOform-guided prediction of epiTOPEs in cancer
Fig 5
Splicing epitopes in two melanoma cohorts.
(A) Total number of events and subset of protein-affecting events in the melanoma cohorts treated with anti-CTLA4 and with anti-PD1. (B) Distribution of the number of candidate tumor-specific splicing-derived neoepitopes (splicing-epitopes) and self-epitopes that would be depleted in the altered isoform (self-epitopes). (C) Distribution of the number of candidate epitopes from (B), separated by HLA-type.